Literature DB >> 10354022

Human leucocyte antigen class II associations in chronic idiopathic urticaria.

B F O'Donnell1, C M O'Neill, D M Francis, N Niimi, R M Barr, R J Barlow, A Kobza Black, K I Welsh, M W Greaves.   

Abstract

The major histocompatibility complex (MHC) acts as a marker for self during T-cell ontogeny and is associated with the pathogenesis of many autoimmune diseases. Recent investigations have shown about 30% of patients with chronic idiopathic urticaria (CIU) have IgG autoantibodies against the high-affinity IgE receptor, FcepsilonRI, or IgE. A link between MHC class II alleles and CIU has not been reported previously. DNA was extracted from blood of 100 Caucasian patients with CIU, and the MHC class II type determined using the polymerase chain reaction with sequence-specific primers, testing for DRB and DQB1 alleles. The frequency of alleles in CIU patients was compared with that found in 603 controls. Further human leucocyte antigen (HLA) typing on patient subsets, classified by the patients' responses to intradermal injection of autologous serum and their serum-induced histamine release from basophil leucocytes of healthy donors, was undertaken. HLA DRB1*04 (DR4) and its associated allele, DQB1*0302 (DQ8), are raised in CIU patients compared with a control population (P = 2 x 10-5 and P = 2 x 10-4, respectively). HLA DRB1*15 (DR15) and its associated allele, DQB1*06 (DQ6), are significantly less frequently associated with CIU. The HLA DRB1*04 association is particularly strong (corrected P = 3.6 x 10-6) for patients whose serum has in vivo and in vitro histamine-releasing activity. HLA class II typing is consistent with the concept that CIU is a heterogeneous disease, and supports an autoimmune pathogenesis in a subset of patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354022     DOI: 10.1046/j.1365-2133.1999.02815.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  26 in total

Review 1.  Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease.

Authors:  Clifton O Bingham
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

Review 2.  Chronic spontaneous urticaria: an autoimmune disease? A revision of the literature.

Authors:  Gabriele Di Lorenzo; Maria Stefania Leto-Barone; Simona La Piana; Aurelio Seidita; Giovam Battista Rini
Journal:  Clin Exp Med       Date:  2012-05-15       Impact factor: 3.984

3.  Association of HLA-DRB1, DQB1 alleles with chronic urticaria.

Authors:  Jing Chen; Zhijian Tan; Jiawen Li; Ping Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

4.  Chronic Urticaria : Expanding the Autoimmune Kaleidoscope.

Authors:  Y K Sharma; Vinay Gera; V D Tiwari
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.

Authors:  Marco Folci; Giacomo Ramponi; Enrico Brunetta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Autoimmunity and complement in the pathogenesis of chronic urticaria.

Authors:  Alexander M Marsland
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

Review 7.  Urticaria and autoimmunity: where are we now?

Authors:  Jenny M Stitt; Stephen C Dreskin
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

Review 8.  [Infections and chronic spontaneous urticaria. A review].

Authors:  B Wedi; U Raap; D Wieczorek; A Kapp
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

9.  Progress and challenges in the understanding of chronic urticaria.

Authors:  Marta Ferrer; Allen P Kaplan
Journal:  Allergy Asthma Clin Immunol       Date:  2007-03-15       Impact factor: 3.406

10.  Urticaria and infections.

Authors:  Bettina Wedi; Ulrike Raap; Dorothea Wieczorek; Alexander Kapp
Journal:  Allergy Asthma Clin Immunol       Date:  2009-12-01       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.